The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.
about
Dendritic cell-based vaccine efficacy: aiming for hot spotsSafety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic reviewDefining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials' experience.Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilitiesIdentification of glypican-3-derived long peptides activating both CD8(+) and CD4(+) T cells; prolonged overall survival in cancer patients with Th cell responseT cell responses to viral infections - opportunities for Peptide vaccination.Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs.Indoleamine 2,3-dioxygenase vaccination.A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine.Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.Intradermal injection of low dose human regulatory T cells inhibits skin inflammation in a humanized mouse model.
P2860
Q28082680-C3CCBEDD-53B0-4A45-9A21-31B7AABC6F62Q28084805-9A55C434-1A69-4410-B1C7-DCE03CB5F159Q30278652-20F1F3CD-3271-46FF-B463-BCD4169B9960Q30412094-70D71F27-71BD-4DDF-A85A-24E1056F1834Q31152863-979FCA02-F919-4CBE-9067-04B1B0244524Q36597336-3660EF22-BCD3-474A-AAE1-F3EE51A46D5EQ37718978-04C918C6-168F-41E7-8EDD-AEE486DAA712Q42594097-0B1D31BD-D9F7-4333-9FD6-131DC1ABC2A0Q43196238-98DF3509-1E4E-469B-94F1-60865E2F66F9Q45073466-A29A5650-D484-40DB-A7EF-650E1C79CDCEQ53415023-F0A28825-09AD-471D-B11F-7FE1A9E163CAQ55386489-80970B12-5604-40C3-9E56-E366C317C763Q55667006-49569EE2-6C52-446D-BE6E-FBDE042271F8
P2860
The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The vaccine-site microenvironm ...... or without melanoma peptides.
@ast
The vaccine-site microenvironm ...... or without melanoma peptides.
@en
type
label
The vaccine-site microenvironm ...... or without melanoma peptides.
@ast
The vaccine-site microenvironm ...... or without melanoma peptides.
@en
prefLabel
The vaccine-site microenvironm ...... or without melanoma peptides.
@ast
The vaccine-site microenvironm ...... or without melanoma peptides.
@en
P2093
P2860
P1476
The vaccine-site microenvironm ...... or without melanoma peptides.
@en
P2093
Donna H Deacon
Gina R Petroni
James W Patterson
Jochen T Schaefer
Kerrington R Molhoek
Louis B Brill
Rebecca C Harris
P2860
P356
10.1097/CJI.0B013E31823731A4
P577
2012-01-01T00:00:00Z